89 related articles for article (PubMed ID: 12396836)
1. CD4(+) bias in T cells cloned from a CML patient with active graft versus leukemia effect.
Dodi IA; Van Rhee F; Forde HC; Roura-Mir C; Jaraquemada D; Goldman JM; Madrigal JA
Cytotherapy; 2002; 4(4):353-63. PubMed ID: 12396836
[TBL] [Abstract][Full Text] [Related]
2. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen.
Jiang YZ; Mavroudis D; Dermime S; Hensel N; Couriel D; Molldrem J; Barrett AJ
Br J Haematol; 1996 Jun; 93(3):606-12. PubMed ID: 8652381
[TBL] [Abstract][Full Text] [Related]
3. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
[TBL] [Abstract][Full Text] [Related]
4. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH
Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118
[TBL] [Abstract][Full Text] [Related]
5. Cellular and cytokine-mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia.
Jiang YZ; Barrett AJ
Exp Hematol; 1995 Oct; 23(11):1167-72. PubMed ID: 7556526
[TBL] [Abstract][Full Text] [Related]
6. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.
Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ
Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263
[TBL] [Abstract][Full Text] [Related]
7. Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing.
Matte CC; Cormier J; Anderson BE; Athanasiadis I; Liu J; Emerson SG; Pear W; Shlomchik WD
Blood; 2004 Jun; 103(11):4353-61. PubMed ID: 14982874
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
[TBL] [Abstract][Full Text] [Related]
9. Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs.
Fujiwara H; Sconocchia G; Melenhorst J; Eniafe R; Nakamura R; Hensel N; Barrett AJ
Bone Marrow Transplant; 2003 Aug; 32(4):371-8. PubMed ID: 12900773
[TBL] [Abstract][Full Text] [Related]
10. Specific recognition of human leukemic cells by allogeneic T cell lines.
Sosman JA; Oettel KR; Hank JA; Fisch P; Sondel PM
Transplantation; 1989 Sep; 48(3):486-95. PubMed ID: 2571206
[TBL] [Abstract][Full Text] [Related]
11. A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes.
Yazaki M; Takahashi T; Andho M; Akatsuka Y; Ito T; Miyake Y; Ito Y; Nakamura S; Wada Y
Bone Marrow Transplant; 1999 Jul; 24(2):129-37. PubMed ID: 10455340
[TBL] [Abstract][Full Text] [Related]
12. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
[TBL] [Abstract][Full Text] [Related]
13. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
14. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
[TBL] [Abstract][Full Text] [Related]
15. Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Nadal E; Garin M; Kaeda J; Apperley J; Lechler R; Dazzi F
Leukemia; 2007 Mar; 21(3):472-9. PubMed ID: 17215853
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia as an immunological target.
Lim SH; Coleman S
Am J Hematol; 1997 Jan; 54(1):61-7. PubMed ID: 8980262
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant.
Matte-Martone C; Venkatesan S; Tan HS; Athanasiadis I; Chang J; Pavisic J; Shlomchik WD
J Immunol; 2011 Aug; 187(4):1653-63. PubMed ID: 21768400
[TBL] [Abstract][Full Text] [Related]
18. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.
Falkenburg JH; Wafelman AR; Joosten P; Smit WM; van Bergen CA; Bongaerts R; Lurvink E; van der Hoorn M; Kluck P; Landegent JE; Kluin-Nelemans HC; Fibbe WE; Willemze R
Blood; 1999 Aug; 94(4):1201-8. PubMed ID: 10438707
[TBL] [Abstract][Full Text] [Related]
19. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression.
Collins RH; Rogers ZR; Bennett M; Kumar V; Nikein A; Fay JW
Bone Marrow Transplant; 1992 Oct; 10(4):391-5. PubMed ID: 1422499
[TBL] [Abstract][Full Text] [Related]
20. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation.
Marijt WA; Kernan NA; Diaz-Barrientos T; Veenhof WF; O'Reilly RJ; Willemze R; Falkenburg JH
Bone Marrow Transplant; 1995 Jul; 16(1):125-32. PubMed ID: 7581111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
